183
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis

, , , , , , , , ORCID Icon, , , , , , , , & ORCID Icon show all
Pages 1257-1266 | Received 27 Apr 2023, Accepted 06 Jul 2023, Published online: 29 Jul 2023

Figures & data

Table 1 Baseline Characteristics of the Patients Before and After PSM

Figure 1 Kaplan-Meier plots: The triple therapy group exhibited longer mOS and mPFS than that of the control group before (a and b) and after (c and d) PSM.

Figure 1 Kaplan-Meier plots: The triple therapy group exhibited longer mOS and mPFS than that of the control group before (a and b) and after (c and d) PSM.

Table 2 Analyses of Prognostic Factors for Survival After PSM

Table 3 Analyses of Prognostic Factors for Progression-Free Survival After PSM

Figure 2 Survival curve of AFP (≥ 400ng/mL/<400ng/mL) group (a), ALP (≥ 125u/L/< 125u/L) group (b), PVTT group (c).

Figure 2 Survival curve of AFP (≥ 400ng/mL/<400ng/mL) group (a), ALP (≥ 125u/L/< 125u/L) group (b), PVTT group (c).

Data Sharing Statement

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author (Lanpaoxiansheng @126.com).